GlassScriptPhysician profile
Joseph Bailes
$1,857,226.86
in general payments reported to CMS, 2019-2025
10 companies · $64K in 2025
The $64K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275K · 2020: $251K · 2021: $155K · 2022: $105K · 2023: $951K · 2024: $56K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $770K · Consulting Fee: $300K · Travel and Lodging: $1,659 · Food and Beverage: $92.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $769,713.00 |
| Consulting Fee | $300,000.00 |
| Travel and Lodging | $1,659.24 |
| Food and Beverage | $92.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $943,019.28 | 2020-2023 | |
| Taiho Oncology, INC. | $267,099.57 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $232,449.22 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Jazz Pharmaceuticals INC. | $225,451.82 | 2019-2022 | |
| Chromacode, INC | $92,000.00 | 2023 | |
| Cardinal Health 110 LLC | $57,018.54 | 2019-2020 | |
| Coherus Oncology, INC. | $20,000.00 | 2020 | |
| Genzyme Corporation | $13,313.43 | 2019-2020 | |
| Kite Pharma, INC. | $5,000.00 | 2019 | |
| Advanced Accelerator Applications | $1,875.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,862,463.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Bailes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.